InterCure Ltd.

NasdaqGM:INCR 주식 보고서

시가총액: US$82.6m

InterCure 과거 수익 실적

과거 기준 확인 0/6

InterCure has been growing earnings at an average annual rate of 1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 45.1% per year.

주요 정보

1.0%

수익 성장률

10.7%

EPS 성장률

Pharmaceuticals 산업 성장6.0%
매출 성장률45.1%
자기자본 수익률-14.6%
순이익-24.1%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

Jun 30

InterCure: Bargain Israel Cannabis Play

Apr 22

InterCure: A Leader In Global Cannabis

Sep 06

InterCure reports Q2 results

Aug 15

InterCure Is Growing In The Massive Global Cannabis Market

Jun 07

IntureCure: Israel Recreation Cannabis Boom On The Way

Feb 16

InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)

Nov 08

InterCure: Internationally Profitable Cannabis (Podcast Transcript)

Sep 19

InterCure: Ignored Uplisting

Sep 09

수익 및 비용 분석

InterCure 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqGM:INCR 수익, 비용 및 수입 (ILS Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 24273-66930
31 Mar 24312-61960
31 Dec 23356-62980
30 Sep 23388-201030
30 Jun 23415211101
31 Mar 23408321091
31 Dec 22389451021
30 Sep 2236333961
30 Jun 2232424801
31 Mar 2227415671
31 Dec 212205571
30 Sep 2116717431
30 Jun 2112820352
31 Mar 219413302
31 Dec 2065-37272
30 Sep 2040-63262
30 Jun 2020-80322
31 Mar 2011-91412
31 Dec 199-6832
30 Sep 1977811
30 Jun 19518720
31 Mar 19227580
31 Dec 180-13100
30 Sep 180-1050
30 Jun 180-810
31 Mar 180-710
31 Dec 170-610
30 Sep 170-410
30 Jun 170-210
31 Mar 170-210
31 Dec 160010
30 Sep 160020
30 Jun 160-120
31 Mar 161020
31 Dec 151-220
30 Sep 152-130
30 Jun 153-230
31 Mar 154-440
31 Dec 146-460
30 Sep 147-560
30 Jun 147-560
31 Mar 148-670
31 Dec 138-780

양질의 수익: INCR is currently unprofitable.

이익 마진 증가: INCR is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: INCR is unprofitable, but has reduced losses over the past 5 years at a rate of 1% per year.

성장 가속화: Unable to compare INCR's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: INCR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


자기자본 수익률

높은 ROE: INCR has a negative Return on Equity (-14.58%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기